Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 27, 2026Journal of Clinical MedicineOpen Access

Comparative Real-World Outcomes of OnabotulinumtoxinA and CGRP Monoclonal Antibodies in Chronic Migraine

View Full Paper
Ask AI
Bookmark
Share

Authors

CLC Koo Seen LinCCChen‐Chih ChungJCJia‐Hung Chen

Discussion

Loading...

Member takes

Overview

Retrospective cohort study compares acute triptan prescriptions and return visits for chronic migraine patients receiving two treatments, suggesting distinct healthcare utilization patterns.

Key Points

  • This study aims to compare the effects of onabotulinumtoxinA and CGRP monoclonal antibodies on healthcare utilization in chronic migraine patients.
  • Conducted a retrospective cohort study using TriNetX electronic health record database from 2018 to 2024.
  • Matched adults with chronic migraine initiating onabotulinumtoxinA or CGRP monoclonal antibody by propensity score (1:1).
  • Assessed primary outcomes of time to acute triptan prescription and time to first migraine-related return visit during follow-up.
  • OnabotulinumtoxinA showed a lower hazard of acute triptan prescription compared to CGRP monoclonal antibodies (HR 0.513, 95% CI 0.481–0.546; p<0.001).
  • Migraine-related return visits were similar between groups (HR 1.008, 95% CI 0.977–1.039; p=0.69).

Cite This Study

Lin et al. (2026) studied this question.

synapsesocial.com/papers/6a3f6843aea7db3c1953f6c9https://doi.org/10.3390/jcm15134963
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Combination preventive therapy with onabotulinumtoxinA and atogepant for chronic migraine: A 24-week, prospective, real-world evaluation (SYNERGY study)2025
  2. 2Real world effectiveness of anti-CGRP monoclonal antibodies over three consecutive one-year treatment cycles: An intention-to-treat analysis2025
  3. 3Prescription of Monoclonal Antibodies Against Calcitonin Gene‐Related Peptide for the Prophylaxis of Migraine in Austria: A Retrospective, Longitudinal Analysis of Nationwide Insurance Data2025 · 1 citations
  4. 4Sequential use of OnabotulinumtoxinA and Erenumab in Chronic Migraine: Retrospective Real-World Report on Bidirectional Switching2025
  5. 5Anti-CGRP monoclonal antibodies and migraine with aura: a narrative review2025